# US 6,730,664 B1 · Formulations for parenteral use of estramustine phosphate and sulfoalkyl ether cyclodextrins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,664 B1
- Document ID: US6730664B1
- Status: Granted
- Kind: B1
- Application number: 10/070,416
- Filed: 2002-03-15
- Granted: 2004-05-04
- Earliest claimed: 1999-09-16
- Assignees: Pharmacia Italia S.p.A.
- Inventors: Lorena Muggetti; Paolo Colombo; Alessandro Martini; Giovanni Buzzi
- Web page: https://patentgrep.com/patent/US6730664B1

## CPC

- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/661: Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion {or mevinphos}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/40: Cyclodextrins; Derivatives thereof
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/08: of the prostate
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A pharmaceutical formulation which comprises a parenterally acceptable carrier or diluent, estramustine phosphate and a sulfoalkyl ether cyclodextrin. The formulation can be administered according to a combined chemotherapy regimen in association with one or more chemotherapeutic agents. The formulation also enables estramustin phosphate to be administered with no side effects at the site of injection.

## Claims

### Claim 1

A pharmaceutical formation which comprises a parenterally acceptable carrier or diluent and estramustine phosphate and a sulfoalkyl ether cyclodextrine.

### Claim 2 (depends on 1)

A formulation according to claim 1, wherein the weight ratio of estramustine phosphate to the sulfoalkyl ether cyclodextrin is from about 1:1 to about 1:5.

### Claim 3 (depends on 1)

A formulation according to claim 1, which is in single infusing doseage from comprising at least 1300 mg of the estramustine phosphate.

### Claim 4 (depends on 1)

A formulation according to claim 1, which is in single infusing doseage from comprising at least 950 mg/m2 of the estramustine phosphate.

### Claim 5 (depends on 1)

A formulation according to claim 1, wherein the sulfoalkyl ether cyclodextrine is a straight or branched C1-C6 sulfoalkyl cyclodextrine.

### Claim 6 (depends on 5)

A formulation according to claim 5, wherein the sulfoalkyl ether cyclodextrin is sulfobutyl ether β-cyclodextrin.

### Claim 7 (depends on 1)

A formulation according to claim 1, wherein the estramustine phosphate is in the form of a pharmaceutically acceptable salt for intravenous use.

### Claim 8 (depends on 7)

A formulation according to claim 7 wherein the estramustine phosphate is in the form of N-methyl glucamine salt.

### Claim 9 (depends on 1)

A formulation according to claim 1 wherein the parenterally acceptable carrier is a physiological solution for parenteral use which contains the sulfoalkyl ether cyclodextrin, and the extramustine phosphate is in lyophilized form.

### Claim 10 (depends on 1)

A method for treatment of cancer comprising parenterally administering the formulation of claim 1 to a patient in need thereof, whereby the cancer is treated.

### Claim 11 (depends on 10)

A method as claimed in claim 10 wherein the cancer is prostate cancer, breast cancer, melanoma, lung cancer, pancreatic cancer, colorectal cancer, ovarian cancers or cancer of the brain.

### Claim 12 (depends on 10)

The method of claim 10, wherein the formulation is intravenously administered.

### Claim 13 (depends on 1)

A method of suppressing or reducing side-effects associated with intravenous administration of estramustine phosphate and pharmaceutically acceptable salts thereof comprising administering the formulation of claim 1 to a patient in need thereof, whereby the side-effects are suppressed or reduced.

### Claim 14 (depends on 13)

The method according to claim 13 wherein the side effects comprise ulcerative lesions and thrombophlebitis at the site of injection.

### Claim 15

A product which comprises
(i) a pharmaceutical formulation which comprises a parenterally acceptable carrier or diluent, estramustine phosphate and a sulfoalkyl ether cyclodextrin, and
(ii) one or more chemotherapeutic agents; as a combined preparation for simultaneous, separate or sequential use in anticancer therapy.

### Claim 16 (depends on 15)

A product according to claim 15 wherein the sulfoalkyl ether cyclodextrin is sulfobutyl ether β-cyclodextrin.

### Claim 17 (depends on 15)

A product according to claim 15 wherein the chemotherapeutic agent is selected from taxane, taxane derivatives, CPT-11, camptothecin and derivatives thereof, doxorubicin, idarubicin or epirubicin, etoposide, navelbine, vinblastine, carboplatin, cisplatin, SU 6668 and SU 5416.

### Claim 18 (depends on 17)

The product of claim 17, wherein the chemotherapeutic agent is encapsulated within liposomes.

### Claim 19 (depends on 15)

A method for treatment of cancer comprising parenterally administering the product of claim 15 to a patient, whereby the cancer is treated.

### Claim 20 (depends on 19)

The method according to claim 19, wherein the cancer is prostate cancer, breast cancer, melanoma, lung cancer, pancreatic cancer, colorectal cancer, ovarian cancer or cancer of the brain.

### Claim 21 (depends on 19)

The method of claim 19, wherein the product is intravenously administered.

### Claim 22

A product which comprises estramustine phosphate in lyophilized form and a physiological solution for parenteral use containing a sulfoalkyl ether cyclodextrin.
